Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth

Jingying Zheng, Shuhua Zhao, Xiaolin Yu, Shuang Huang, HongYan Liu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

CD44 and EpCAM play crucial roles in intraperitoneal ovarian cancer development. In this study, we developed an RNA-based bispecific CD44-EpCAM aptamer that is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. With the aid of a panel of ovarian cancer cell lines, we found that bispecific CD44-EpCAM aptamer was much more effective than either single CD44 or EpCAM aptamer in the ability to inhibit cell growth and to induce apoptosis. When these aptamers were tested in intraperitoneal ovarian cancer xenograft model, bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth much more significantly than single CD44 and EpCAM aptamer either alone or in combination. The enhanced efficacy of bispecific CD44-EpCAM aptamer is most likely to be attributed to its increased circulation time over the single aptamers. Moreover, we showed that bispecific CD44-EpCAM aptamer exhibited no toxicity to the host and was unable to trigger innate immunogenicity. Our study suggests that bispecific CD44-EpCAM aptamer may represent a promising therapeutic agent against advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1373-1388
Number of pages16
JournalTheranostics
Volume7
Issue number5
DOIs
StatePublished - Mar 23 2017

Fingerprint

Ovarian Neoplasms
Growth
Epithelial Cell Adhesion Molecule
Double-Stranded RNA
Heterografts
RNA
Apoptosis
Cell Line

Keywords

  • Aptamer
  • Bispecific molecule
  • CD44
  • EpCAM
  • Intraperitoneal tumor growth

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. / Zheng, Jingying; Zhao, Shuhua; Yu, Xiaolin; Huang, Shuang; Liu, HongYan.

In: Theranostics, Vol. 7, No. 5, 23.03.2017, p. 1373-1388.

Research output: Contribution to journalArticle

Zheng, Jingying ; Zhao, Shuhua ; Yu, Xiaolin ; Huang, Shuang ; Liu, HongYan. / Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth. In: Theranostics. 2017 ; Vol. 7, No. 5. pp. 1373-1388.
@article{e5e272d0be744a959b275328a8af4041,
title = "Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth",
abstract = "CD44 and EpCAM play crucial roles in intraperitoneal ovarian cancer development. In this study, we developed an RNA-based bispecific CD44-EpCAM aptamer that is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. With the aid of a panel of ovarian cancer cell lines, we found that bispecific CD44-EpCAM aptamer was much more effective than either single CD44 or EpCAM aptamer in the ability to inhibit cell growth and to induce apoptosis. When these aptamers were tested in intraperitoneal ovarian cancer xenograft model, bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth much more significantly than single CD44 and EpCAM aptamer either alone or in combination. The enhanced efficacy of bispecific CD44-EpCAM aptamer is most likely to be attributed to its increased circulation time over the single aptamers. Moreover, we showed that bispecific CD44-EpCAM aptamer exhibited no toxicity to the host and was unable to trigger innate immunogenicity. Our study suggests that bispecific CD44-EpCAM aptamer may represent a promising therapeutic agent against advanced ovarian cancer.",
keywords = "Aptamer, Bispecific molecule, CD44, EpCAM, Intraperitoneal tumor growth",
author = "Jingying Zheng and Shuhua Zhao and Xiaolin Yu and Shuang Huang and HongYan Liu",
year = "2017",
month = "3",
day = "23",
doi = "10.7150/thno.17826",
language = "English (US)",
volume = "7",
pages = "1373--1388",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "5",

}

TY - JOUR

T1 - Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth

AU - Zheng, Jingying

AU - Zhao, Shuhua

AU - Yu, Xiaolin

AU - Huang, Shuang

AU - Liu, HongYan

PY - 2017/3/23

Y1 - 2017/3/23

N2 - CD44 and EpCAM play crucial roles in intraperitoneal ovarian cancer development. In this study, we developed an RNA-based bispecific CD44-EpCAM aptamer that is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. With the aid of a panel of ovarian cancer cell lines, we found that bispecific CD44-EpCAM aptamer was much more effective than either single CD44 or EpCAM aptamer in the ability to inhibit cell growth and to induce apoptosis. When these aptamers were tested in intraperitoneal ovarian cancer xenograft model, bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth much more significantly than single CD44 and EpCAM aptamer either alone or in combination. The enhanced efficacy of bispecific CD44-EpCAM aptamer is most likely to be attributed to its increased circulation time over the single aptamers. Moreover, we showed that bispecific CD44-EpCAM aptamer exhibited no toxicity to the host and was unable to trigger innate immunogenicity. Our study suggests that bispecific CD44-EpCAM aptamer may represent a promising therapeutic agent against advanced ovarian cancer.

AB - CD44 and EpCAM play crucial roles in intraperitoneal ovarian cancer development. In this study, we developed an RNA-based bispecific CD44-EpCAM aptamer that is capable of blocking CD44 and EpCAM simultaneously by fusing single CD44 and EpCAM aptamers with a double stranded RNA adaptor. With the aid of a panel of ovarian cancer cell lines, we found that bispecific CD44-EpCAM aptamer was much more effective than either single CD44 or EpCAM aptamer in the ability to inhibit cell growth and to induce apoptosis. When these aptamers were tested in intraperitoneal ovarian cancer xenograft model, bispecific CD44-EpCAM aptamer suppressed intraperitoneal tumor outgrowth much more significantly than single CD44 and EpCAM aptamer either alone or in combination. The enhanced efficacy of bispecific CD44-EpCAM aptamer is most likely to be attributed to its increased circulation time over the single aptamers. Moreover, we showed that bispecific CD44-EpCAM aptamer exhibited no toxicity to the host and was unable to trigger innate immunogenicity. Our study suggests that bispecific CD44-EpCAM aptamer may represent a promising therapeutic agent against advanced ovarian cancer.

KW - Aptamer

KW - Bispecific molecule

KW - CD44

KW - EpCAM

KW - Intraperitoneal tumor growth

UR - http://www.scopus.com/inward/record.url?scp=85016713143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016713143&partnerID=8YFLogxK

U2 - 10.7150/thno.17826

DO - 10.7150/thno.17826

M3 - Article

C2 - 28435472

AN - SCOPUS:85016713143

VL - 7

SP - 1373

EP - 1388

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 5

ER -